Page 9 - Data Collective News Today

SentinelOne IPO Filing Reveals Surging Sales, Strength Of Channel Endpoint security vendor SentinelOne revealed skyrocketing sales and a channel-first selling motion in its IPO filing, with solution providers accounting for 96 percent of the company’s revenue. By Michael Novinson June 03, 2021, 07:41 PM EDT SentinelOne became the second cybersecurity company to pursue an initial public offering this year, revealing skyrocketing sales, growing losses and a cha...

"Bloomberg" reported several months ago that SentinelOne will be looking for a $10 billion valuation.

London-based Cervest closes $30 million Series A funding led by venture capital firm Draper Esprit.

/PRNewswire/ -- Nylas, a pioneer and leading provider of Productivity Infrastructure solutions for modern software development teams, today announced its...

About this event Public and private investment in quantum technology is on the rise around the world. Current estimates state the global industry will be valued at close to $86 billion by 2040. What does this mean for the Australian market and our homegrown Australian startups? How can budding entrepreneurs get a slice of the action? Cicada Innovations in partnership with the Sydney Quantum Academy’s ‘Quantum Innovators Network’ presents a panel of quantum founders to discuss th...

Posted on 802 Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round. The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Invest...

Alchemab completes £60m Series A funding to advance novel antibody platform 15th April 2021 Cambridge, UK-based Alchemab Therapeutics has raised £60m ($82m) in a Series A funding round, in a bid to advance its target-agnostic drug discovery platform. The firm announced that the round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC, DHVC, SV Health Investors and the Dementia Discovery Fund. The funding will be used to advance Alchemab’s novel...

Alchemab Therapeutics Raises £60M in Series A Financing Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round. The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company, which was created by SV Health I...

Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer Share Rare Daily Staff Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, said it closed an $82 million (£60 million) series A financing round. RA Capital Management led the financing, with participation by an international syndicate that included Lightstone Ventures, Dat...

(1) Distinguished leader Steve Neat joins Alation to accelerate growth and regional expansion, enhance customer intimacy Alation Inc., the leader in enterprise data intelligence solutions, today announced the appointment of Steve Neat as its new Vice President of Sales for Europe, the Middle East, and Africa (EMEA). Steve will address the ever-increasing demand for Alation in EMEA; develop new sales channels; and contribute to strategies that drive business value for Alations international...